


Save the date

14<sup>th</sup> & 15<sup>th</sup> October 2019

7<sup>th</sup> edition



Location

Le Saint Paul Hotel Nice - France

# Heart Failure Guidelines Forum Preliminary program



# **Monday 14th October 2019**

**12:00–12:45:** Welcome discussion

**13:00–13:30:** Session 1 – Heart failure guidelines process – Rules of engagement.

- How are the different guidelines developed?
- US and European perspectives
- Clinical practice update Consensus paper

**13:30–14:30:** Session 2 – Diagnosis of HFpEF and its treatment

**14:30–15:15:** Session 3 – Diagnosis of HFmEF and its treatment

• The role of Beta-blockers, Candesartan and Spironolactone

**15:15–16:30:** Session 4 – Treatment algorithms for HFrFF

- Should Sacubitril/Valsartan be considered first line therapy if so in whom?
- How to add new medications to this algorithm in the future?

#### 16:30-16:45 BREAK

**16:45–17:45:** Session 5 – Electrical devices and ablation for HF

**17:45–19:00:** Session 6 – Targeting valvular disease as a co-morbidity of heart failure

 Adressing Functional Mitral Regurgitation and Tricuspid Regurgitation

**19:00–19:30:** Session 7 – Ad hoc Q & A session (part 1)

FROM 20:00: DINNER

#### **Format**

A series of short presentations and discussions with a focus on practical examples, case studies and interactivity between Faculty members.

### Who should attend?

Attendees include industry representatives with interest in clinical trials, product development, market access, guidelines development and implementation, patients' advocacy specialists, clinical research organizations and payers.

#### **About TMA**

The Translational Medicine
Academy (TMA) is an
international academic
Foundation with focused
activities in Mission Critical Areas
of high public health importance
having significant professional
and patient therapeutic and
educational gaps.

# Why a Heart Failure Guidelines Forum?

The objective is to better understand the existing Heart Failure guidelines development process and its implications in clinical practice. It is not to develop new guidelines, but to gather a multidisciplinary panel of leading international experts to discuss the latest evidence, ongoing research and controversial issues that have implications for the development of clinical practice guidelines.

# **Educational objectives**

At the end of the meeting, all participants will have a better understanding of the unmet needs and knowledge gaps that need to be addressed by future research and development efforts, and of the most appropriate ways of progressing to conciliate and take advantage of clinical, societal, evidence-based medicine and regulatory requirements.

## **Tuesday 15<sup>th</sup> October 2019**

**08:45–09:30:** Session 8 – Acute heart failure

- Procalcitonin in AHF to guide therapy
- Diuretics

**09:30 -10:30:** Session 9 - Supportive approaches to enable life-saving therapies

• Shall we change the treatment paradigm of hyperkalaemia to optimize RAASi therapy

**10:30–11:30:** Session 10 – New strategies for better care of co-morbidities in HF: do we need to adjust the treatment algorithm?

- · Update on sleep apnea
- New evidence regarding IV Iron
- Heart failure and diabetes : prevention and treatment

#### 11:30-11:45 BREAK

**11:45–12:15:** Session 11 – Heart failure in special populations

 How do account for frailty, stroke, cardio-oncology in the guidelines

**12:15–12:45:** Session 12 – TMA interactive discussion on guidelines

**12:45–13:45:** Session 13 – Ad hoc Q & A session (part 2)

**13:45–14:30:** Final comments and close – lunch

This event is registered with MedTech Europe and declared (provisionally) compliant: https://www.ethicalmedtech.eu/

**CLOSING** 

# Meet our panelists

# Chairs



Prof. William T. Abraham

MD, FACP, FACC, FAHA, FESC, **FRCPE** 

Professor of Medicine, Physiology, and Cell Biology College of Medicine Distinguished Professor Division of Cardiovascular Medicine

The Ohio State University, USA



**Prof. Stefan Anker** 

MD. PhD. FESC Professor of cardiology and Cachexia Research Department of Cardiology Charité Campus Virchow-Klinikum Berlin, Germany



**Prof. Javed Butler** 

MD, MPH, MBA Professor and Chairman of the Department of Medicine at the University of Mississippi in Jackson, Mississippi, USA Patrick H. Lehan Chair in

Cardiovascular Research. Professor of physiology.



**Prof Andrew J.S. Coats** 

DM, DSc, MBA, AO President-elect Heart failure Association of the ESC Academic Vice-President Monash-Warwick Alliance Monash University, Melbourne, Australia University of Warwick, Coventry, UK

# **Experts**

## Faculty members

**Prof. John Cleland, UK** 

Prof. Ileana Piña, USA

**Prof. Faiez Zannad. France** 

- Prof. Kenneth Dickstein, Norway

**Prof. Piotr PONIKOWSKI, Poland** 

Prof. Gerd Hasenfuß, Germany -

**Prof. Petar Seferovic, Serbia** 

Prof. Carolyn Lam, Singapore,

**Prof. Horst Sievert, Germany** 

- Prof. Marco Metra, Italy

Prof. Lynn Warner Stevenson, USA

Regulatory agencies

**Prof. Nathan Mewton, France** 

**Karen Hicks - FDA** 

**Prof. Martin Möckel, Germany** 

Prof. Karl Swedberg, Sweden

**Prof. Adrian Voors, The Netherlands** 

– Giuseppe Rosano - EMA

# Contact us

Organization

Charles Schoen - Operations Director

Tel.: +33 (0) 6 08 18 77 08

Email: charles.schoen@tmacademy.org

Registration William Melhuish

Tel.: + 33 (0) 6 16 54 81 57

E-mail: william@mededgs.com

#### Information & registration:

www.tmacademy.org

An opportunity to meet

a panel of international experts

in Heart Failure

